Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 552Neoplasms 502Carcinoma, Non-Small-Cell Lung 419Prostatic Neoplasms 326Colorectal Neoplasms 310Lung Neoplasms 280Neoplasm Metastasis 233Leukemia, Myeloid, Acute 222Ovarian Neoplasms 205Pancreatic Neoplasms 195Multiple Myeloma 186Recurrence 141Squamous Cell Carcinoma of Head and Neck 140Brain Neoplasms 139Stomach Neoplasms 138Melanoma 132Carcinoma, Hepatocellular 130Endometrial Neoplasms 127Glioblastoma 124Triple Negative Breast Neoplasms 116Precursor Cell Lymphoblastic Leukemia-Lymphoma 115Hematologic Neoplasms 102Head and Neck Neoplasms 100Urinary Bladder Neoplasms 98Carcinoma, Renal Cell 98Lymphoma 97Glioma 94Sarcoma 93Esophageal Neoplasms 90Uterine Cervical Neoplasms 88

Interventions

gedatolisib 1darolutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Genital Diseases, Male × 90 days × Clear all
NCT06190899 2026-04-13

Gedatolisib in Combination With Darolutamide in Metastatic Castration-Resistant Prostate Cancer

Celcuity Inc

Phase 1/2 Recruiting
54 enrolled
Genitourinary

Genital Diseases, Male, Prostatic Diseases, Prostatic Neoplasms, Male Urogenital Diseases, Prostatic Neoplasms, Castration-Resistant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡